Endosense(瑞士)

Endosense

Endosensewww.endosense.comEndosense于2003年在日內(nèi)瓦成立，是一家醫(yī)療科技公司，致力于改善治療心律失常的導管消融術(shù)的功效、安全性和易用性。公司在開發(fā)TactiCath*時率先在導管消融術(shù)中采用了觸點壓力測量，TactiCath是種壓敏消融導管，允許醫(yī)生在實施導管消融術(shù)時實時、客觀地測量接觸力。Endosense得到EdmonddeRothschildInvest mentPartners、Neomed、Gimv、VIPartners、SectoralAssetManagement、YsiosCapitalPartners及InitiativeCapitalRomandie等投資公司的投資支持。Endosenseisamedicaltechnologycompanyfocusedonimprovingtheefficacy,safetyandreproducibilityofcatheterablationforthetreatmentofcardiacarrhythmias.ThecompanyhaspioneeredtheuseofContactForceincatheterablation.Thecompany’sflagshipproductistheTactiCathQuartz®,thefirstforce-sensingablationcathetertogivephysiciansareal-time,objectivemeasureofcontactforceduringthecatheterablationprocedure.AlreadydistributedinEurope,AustraliaandNewZealand,thisforce-sensingcatheterhasundergoneextensivepre-clinicalandclinicalvalidation.Endosense’star